Data & Platforms

This report provides an overview of the digital pathology market from 2023 to 2028. The digital pathology market, as defined in this report, is comprised of revenue from instruments and software sold to clinical, academic, biopharma, and CRO customers, along with service revenues generated by CROs and reference labs.* This market is highly fragmented today, with top vendors providing multiple tools relevant for different aspects of the digital pathology workflow (i.e., slide scanning, slide viewing, image analysis, report generation, and image storage) and many other mid-sized and smaller-sized players that provide tools for individual aspects of the digital pathology workflow (i.e., only AI tools). Many players have formed partnerships with other DP providers, which will likely impact growth for some of the small to mid-sized players as consolidation occurs.

DeciBio conducted 11 interviews with OB/GYNs and KOLs in biotech / VC / pharma to explore key unmet needs / challenges, opportunities for precision medicine, and emerging players in women’s health.

DeciBio conducted 10 interviews with stakeholders at pharmaceutical companies to better understand their perception of established and upcoming digital pathology vendors, as well as key pain points and current perceptions of the technology.

DecBio conducted 10 interviews with KOLs at academic medical centers, pharmaceutical companies, reference labs, and CROs to better understand their perception of established and upcoming NGS instrument vendors, as well as key pain points and predictions for NGS.

DeciBio conducted 11 interviews with KOLs at pharmaceutical companies to understand how pharma spends their money in support of therapeutic / precision medicine development initiatives today, and how these investments may change in the future

BioTrack is the all-in-one data aggregator for busy life science professionals. Discover the latest life science news, publications, and clinical trials that relate to your interests and workflows.

Dexter is a curated community of precision medicine stakeholders across broad and niche fields. We're dedicated to our vision of accelerating innovation by fostering meaningful partnerships.

Next generation therapy trackers (TheraTrack) platform includes dynamic, up-to-date trackers of assets in development across cell therapies, viral gene therapies, nucleic acid based therapies, and antibody-drug conjugates.

The DxBooks cover U.S. labs’ testing behaviors in the areas of oncology biomarkers, infectious disease diagnostics, and SARS-CoV-2 testing.

A medical oncologist at a Northeast Academic NCI Comprehensive Cancer Center discusses their utilization and understanding of MRD and ctDNA monitoring in patients with bladder, renal, and prostate cancers.

DeciBio conducted 10 interviews with academic researchers and biopharma executives to explore how advanced and next-generation proteomics tools have been adopted into research efforts today

DeciBio conducted ~11 interviews with medical oncologists and biopharma executives to understand how minimal residual disease (MRD) testing and ctDNA monitoring are currently integrated into solid tumor care

We forecast that the cancer biomarker testing market size will grow at ~11% p.a. from ~$2.7B in 2017 to ~$3.7B in 2020. The near-term growth is driven primarily by the global personalized medicine initiatives and evolving regulatory and reimbursement landscapes in the U.S. that are designed to make biomarker-based diagnostic tests more accessible to patients

We forecast that the NGS manufacturer market size will reach ~$4.2B in 2020 (a 6% contraction vs. 2019), and grow at 18% p.a. to reach $6.9B in 2023, driven primarily by adoption from clinical customers worldwide.

The sixth edition of this report provides an overview of the life sciences research tools (LSRT) market from 2019 to 2025. Life sciences research tools companies offer instruments, reagents and services to academic, biopharma, applied market, and (non-IVD) clinical customers. This market is consolidated, with top vendors including Agilent, Becton Dickinson, Danaher, Illumina, Merck-EMD Millipore, and Thermo Fisher representing the majority of sales; however, mid-size players (e.g., NanoString Technologies) and smaller emerging players(e.g., Vizgen, Quantum SI) are included in this report as well, as these companies grow rapidly.

This report provides a summary of the current spatial biology market landscape as well as a forward-looking perspective of the spatial biology market from 2022 to 2027.

Liquid biopsies (LBx), which, to-date, have been used largely for genomic profiling and therapy selection, are finding new applications throughout the patient journey and within pharma research. To help predict the future state of the market, we have developed an evaluation framework to identify and assess areas of growth within the liquid biopsy market.

Technologies that profile the tumor microenvironment (TME) have become a central tool for biomarker discovery and validation, especially in the field of immuno-oncology (I/O). In addition to their utility in discovery / translational applications, technologies like multiplex tissue analysis (MTA) and AI-guided digital pathology (DP) are fast solidifying as diagnostics as well. ‍

The fifth edition of this report takes a completely updated and comprehensive look at the SCA market. We assess the SCA market across 6 segments and 31 subsegments.